Skip to main content
. 2019 Oct 15;93(21):e00129-19. doi: 10.1128/JVI.00129-19

FIG 4.

FIG 4

Tumor growth and survival in mice challenged with ID8-Defb29/Vegf-A tumors and treated weekly with 100 μg of CPMV or eCPMV on days 7, 14, 21, 28, 35, and 42 postinoculation. Green arrows indicate the injection time points. (A to C) Tumor growth was monitored by measuring body weight (A), circumference (B), and luciferase expression in the peritoneal cavity (C). Data are means ± standard errors of the means (SEM) (n = 5). Statistical significance was calculated by two-way ANOVA with Tukey’s test. *, P < 0.05; **, P < 0.01; ***, P < 0.0005; ****, P < 0.0001. (D) Survival rates of treated mice. Statistical significance was calculated using the Mantel-Cox log rank test. **, P < 0.01. (E) Representative live-animal imaging of CPMV- and eCPMV-treated mice with ID8-Defb29/Vegf-A-luc tumors (40 days postinoculation).